newsfilter
← Latest News
GlobeNewswire·

BlossomHill Therapeutics Announces Upcoming Presentation for BH-30236, an Oral Macrocyclic CLK Inhibitor, at the 68th American Society of Hematology (ASH) Annual Meeting

BLSM
  • BlossomHill Therapeutics announced a poster presentation on preclinical & clinical data for BH-30236 at the 68th ASH Annual Meeting in New Orleans from December 12-15, 2026.
  • BH-30236 is an orally bioavailable, macrocyclic CDC-like kinase (CLK) inhibitor designed to modulate aberrant alternative pre-mRNA splicing in cancer.
  • The drug is currently in a Phase 1/1b multicenter, open-label, first-in-human trial for adults with relapsed or refractory acute myeloid leukemia (AML) & higher-risk myelodysplastic syndrome (HR-MDS).
  • CEO J. Jean Cui stated the ASH findings validate BH-30236's mechanism of action & its potential to address unmet needs in R/R AML & HR-MDS.
  • The poster presentation titled "BH-30236, a novel macrocyclic clk inhibitor..." will be held on December 14, 2026, at the Ernest N. Morial Convention Center.
  • The U.S. FDA has granted orphan drug designation to BH-30236 for AML treatment.
  • BlossomHill Therapeutics is headquartered in San Diego, California, & leads the company CEO J. Jean Cui, who has three prior FDA-approved drugs.
  • The company's pipeline includes BH-30643 for EGFR-mutant non-small cell lung cancer (NSCLC) & BH-501284, a preclinical KRAS Switch-II inhibitor.